# OnCo record nct07241416 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07241416/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07241416", "NCT07241416" ;
  schema:name "A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer"@en ;
  schema:description "A phase 3 trial of Rezvilutamide run by Jiangsu HengRui Medicine Co., Ltd. in prostate cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07241416/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07241416> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-12-05" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/rezvilutamide/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .